insulin-glargine and Kidney-Failure--Chronic

Glucagon-like peptide 1(GLP-1) receptor agonists are used in patients with type 2 diabetes as hypoglycemic drugs; a growing body of evidence has clarified their renoprotective benefits. We performed a meta-analysis to summarize the most recent evidence on the renal benefits of GLP-1 receptor agonists from clinical trials of patients with type 2 diabetes.. This meta-analysis used a fixed-effects model to estimate the risk ratio (RR) with 95% confidence intervals (CIs) to investigate the effect of GLP-1 receptor agonists on the renal protection. The outcomes were a composite renal outcome, estimated glomerular filtration rate (eGFR) decrease, new macroalbuminuria, doubling of serum creatinine, end-stage renal disease (ESRD) and renal death. We also checked the composite renal outcome of the patient subgroups based on the structural source of human GLP-1 or exendin-4.. Among the 12 articles screened, seven studies involving 48101 patients met pre-specified criteria and were included. In general, the use of GLP-1 receptor agonists reduced the risk of the composite renal outcome by 17% (RR 0·83 [95% CI 0·79-0·88]; P < 0·00001), with no significant interaction in subgroups analysis (P = 0.66); the risk of new-onset of persistent macroalbuminuria was reduced by 25% (RR 0·75 [95%CI 0·69-0·81]; P < 0·00001) compared to placebo. However, GLP-1 receptor agonists had no significant effect on eGFR decrease (RR 0·92 [95% CI 0·83-1.01]; P = 0·09), doubling of serum creatinine (RR 0·97 [95% CI 0·78-1.21]; P = 0·79), or end-stage renal disease (RR 0·81 [95% CI 0·62-1.06]; P = 0·12) compared to placebo or insulin glargine (AWARD-7) in patients with type 2 diabetes.. GLP-1 receptor agonists, regardless of their structural homology, have significant benefits in reducing the risk of the composite renal outcome, especially in new macroalbuminuria compared with placebo or insulin glargine in patients with type 2 diabetes.

Topics: Creatinine; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney Failure, Chronic

We aimed to analyze the impact of basal insulin analogues on glucose variability (GV) in patients with type 2 diabetes (DM) undergoing renal replacement therapy.. Fourteen subjects on insulin therapy for at least 6 months (detemir, n = 7 vs. glargine, n = 7) were sequentially enrolled in this prospective study. Continuous glucose monitoring system (CGMS Gold, Dex Com 7+) was applied for 5 days, over 3 consecutive sessions of hemodialysis (HD). Various glycemic profiles (coefficient of variation-CV of mean glucose) were compared between the day on (HD-on) and the day off (HD-off) dialysis. The CV of at least 3 values of HbA1c (HPLC) since replacement therapy has been applied to assay the long-term GV. Endogenous insulin and insulin resistance (HOMA using fasting glucose and C-peptide levels), fasting lipid profile, quantitative C-reactive protein (CRP) and ferritin (values adjusted for Hb) were measured in serum at inclusion.. The overnight HD-off and HD-on short-term (CV CGMS) GV, overall long-term (CV of HbA1c) GV, CRP and ferritin were reduced in subjects treated with detemir (paired t test, p = 0.0001, 0.0011, 0.036, <0.001, and <0.001 between groups). All participants were insulin-resistant (HOMA-IR > 3).. Insulin-resistant patients with type 2 diabetes undergoing hemodialysis for end-stage renal disease on insulin detemir exhibit lower glycemic variability and pro-inflammatory profile than with insulin glargine.

Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Kidney Failure, Chronic; Male; Middle Aged; Prognosis; Prospective Studies; Renal Replacement Therapy; Time Factors

Chronic kidney disease (CKD) is a silent disorder that is under-recognized. It is most often diagnosed by biochemical abnormalities. The combination of age, ethnicity, gender, and serum creatinine yields the best overall index of kidney function, and the estimated glomerular filtration rate (GFR) must be readily available for clinical practitioners to facilitate identification of CKD. The detection of persistent proteinuria also heralds the presence of CKD, but this sign is often ignored. A detailed case study is presented to demonstrate the evolution of CKD and its insidious progression to a multifaceted and complex disorder. Delineation of the complications of CKD permits the adaptation of a collaborative action plan between primary care physicians and nephrologists, and sample approaches are outlined.

Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Bone Density Conservation Agents; Calcium; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Kidney Failure, Chronic; Metoprolol; Nitroglycerin; Sulfonamides; Thiophenes

Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Kidney Failure, Chronic; Middle Aged; Renal Dialysis